Active Clinical Trials

If you would like to be considered for one of the clinical trials listed below please contact our Clinical Research Team at:

DukeDermatologyClinicalResearch@duke.edu
Phone: 919-684-8132

Learn More about Our Clinical Trials

Active Clinical Trials

Basal Cell Carcinoma

  • A Phase 2 controlled randomized study of the efficacy of L19IL2 or L19TNF or L19IL2/L19TNF intralesional injections for the treatment of locally advanced basal cell carcinoma patients

Squamous Cell Carcinoma

  • A Phase 2 study of intratumoral administration of L19IL2/L19TNF in locally advanced Cutaneous Squamous Cell Carcinoma patients progressing on or intolerant to systemic treatment

Hidradenitis Suppurativa (HS)

  • Role of hormones in hidradenitis suppurativa and other skin diseases.
  • Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository- HS PROGRESS
  • Biorepository of Patients with Hidradenitis Suppurativa (HS): Determination of potential predictors and moderators of treatment response in patients with HS. 
  • A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS).
  • A Study of LAD191 in Adults With Hidradenitis Suppurativa
  • A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic

 

Cutaneous Sarcoidosis

  • A Phase 2/​3 Study of Brepocitinib in Adults With Cutaneous Sarcoidosis

 

Lichen Planopilaris

Lupus

  • A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/​or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory and/​or Intolerant to Antimalarial Therapy (AMETHYST).
  • A Multicenter, Open-Label, Single-Arm, Phase 3, Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 (Litifilimab) in Adult Participants with Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus with or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST LTE)